Clinical Trial Update: The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes [NA]

View source ↗

Summary

A completed clinical trial evaluating the effects of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-2 (GLP-2) on glucagon secretion in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• GIP (glucose-dependent insulinotropic polypeptide)
• GLP-2 (glucagon-like peptide-2)

Snippet

Sponsor: University Hospital, Gentofte, Copenhagen | Conditions: Diabetes Mellitus | NA | Status: COMPLETED